| Aug 9 |
Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call Transcript
|
| Aug 9 |
Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?
|
| Aug 8 |
With 65% ownership of the shares, Ocular Therapeutix, Inc. (NASDAQ:OCUL) is heavily dominated by institutional owners
|
| Aug 7 |
Ocular says FDA views Phase 3 study as appropriate to support NDA
|
| Aug 7 |
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 7 |
Ocular Therapeutix: Q2 Earnings Snapshot
|
| Aug 7 |
Ocular Therapeutix GAAP EPS of -$0.26 misses by $0.04, revenue of $16.44M beats by $0.59M
|
| Aug 7 |
Ocular Therapeutix™ Reports Second Quarter 2024 Results
|
| Aug 7 |
Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD
|
| Aug 6 |
Ocular Therapeutix Q2 2024 Earnings Preview
|
